PMID- 19332960
OWN - NLM
STAT- MEDLINE
DCOM- 20090421
LR  - 20090331
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 121
IP  - 2
DP  - 2009 Mar
TI  - Angiotensin receptor blocker and dihydropyridine calcium channel blocker 
      combinations: an emerging strategy in hypertension therapy.
PG  - 25-39
LID - 10.3810/pgm.2009.03.1974 [doi]
AB  - Hypertension is a leading contributor to the burden of cardiovascular disease. 
      The importance of lowering blood pressure (BP) to reduce the risk of 
      cardiovascular events has been demonstrated in numerous clinical trials. Most 
      patients require combination antihypertensive therapy utilizing agents from 
      complementary drug classes to achieve BP goals. A calcium channel blocker 
      (CCB)/angiotensin receptor blocker (ARB) combination is a rational approach for 
      such an antihypertensive strategy. Benefits of CCB/ARB combination therapy 
      include additive BP-lowering effects and lower incidences of adverse events 
      (AEs). These agents demonstrate benefits associated with their respective drug 
      classes. The ARBs confer stroke protection, renal protection, and tolerability 
      similar to placebo, without dose-related symptomatic and metabolic AEs, while 
      CCBs are beneficial in reducing stroke and treating angina and cardiac ischemia. 
      The efficacy of this combination has been recently investigated in clinical 
      trials wherein amlodipine was combined with olmesartan medoxomil or valsartan. 
      This article discusses the rationale for using CCB/ARB combinations in patients 
      with hypertension.
FAU - Oparil, Suzanne
AU  - Oparil S
AD  - Vascular Biology and Hypertension Program, Division of Cardiovascular Diseases, 
      University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA. 
      soparil@uab.edu
FAU - Weber, Michael
AU  - Weber M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Dihydropyridines)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*administration & dosage/adverse 
      effects/pharmacology
MH  - Calcium Channel Blockers/*administration & dosage/adverse effects/pharmacology
MH  - Dihydropyridines/*administration & dosage/adverse effects/pharmacology
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypertension/*drug therapy
RF  - 99
EDAT- 2009/04/01 09:00
MHDA- 2009/04/22 09:00
CRDT- 2009/04/01 09:00
PHST- 2009/04/01 09:00 [entrez]
PHST- 2009/04/01 09:00 [pubmed]
PHST- 2009/04/22 09:00 [medline]
AID - 10.3810/pgm.2009.03.1974 [doi]
PST - ppublish
SO  - Postgrad Med. 2009 Mar;121(2):25-39. doi: 10.3810/pgm.2009.03.1974.